Cancer drug safety tested in people with liver problems
NCT ID NCT07231991
Summary
This study examines how the body processes an experimental cancer medicine called vepdegestrant in people with liver problems compared to those with normal liver function. Researchers will give a single oral dose to 24 participants and measure how the medicine moves through their bodies over 11 days. The goal is to understand if liver impairment affects drug levels and safety for future cancer treatment development.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.